Report from India - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Report from India
In an effort to balance bilateral trade, India is urging China to increase Indian pharmaceutical imports.

Pharmaceutical Technology
Volume 35, Issue 10, pp. 18-20

Government views

Until recently, India produced 70% of its bulk-drug needs, but that figure has now fallen to 30%. A Commerce Ministry statement of July 16, 2011, notes that the Indian government is worried that the amount of cheap bulk-drug imports from China have led to a sharp fall in the share of domestic production.

Some have called India's low-export penetration into China embarrassing, including P.V. Appaji, executive director of Pharmexcil, the Indian government's pharmaceutical export promotion council. "Take a look at how China is supporting its bulk drug industry," Appaji says. "With financial incentives worth $75 million, foreign multinationals are keen to set up base there. In India, though Big Pharma tends to form close collaborations, such as risk-sharing outsourcing to codevelop drug candidates, very few of them are willing to permanently set up a decent size R&D center here. In order to retain our export advantage, we need to think like China and counter multinationals at their own game."

India's Commerce and Industry Minister Anand Sharma has also gone on record to express disappointment over China not fulfilling its promise of importing more pharmaceutical products from India. In August 2010, at the 8th meeting of the India-China Joint Economic Group, China had assured India that it would give India access through government contracts in sectors like pharmaceuticals and IT. In a statement to India's Parliament on Aug. 24, 2011, Sharma expressed concern that a year had gone by without China fulfilling its promise to import more. He said the matter would be taken up for discussions again with China.

The two nations are planning a series of talks, to begin Sept. 26, 2011, to shape a framework for enhanced economic cooperation in the pharmaceutical, technology, energy, steel, and telecommunication sectors. A goal of the so-called Strategic Economic Dialogue is to figure out how to grow bilateral trade to reach $100 billion by 2015. Discussions will focus, among other topics, on enhancing exchange and cooperation of pharmaceutical API plant supervision.

A. Nair is a freelance writer based in Mumbai.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here